ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon
Benzinga·07/14/2026 07:22:48
语音播报
- PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
- Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial
- Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks
- Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)